DelveInsight’s, “Malaria Pipeline Insight, 2022,” report provides comprehensive insights about 15+ companies and 20+ pipeline drugs in the Malaria pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key takeaways from the Malaria Pipeline Report
Get an overview of the pipeline landscape @ Malaria Pipeline Outlook
Malaria is a life-threatening disease caused by parasites that are transmitted to people through the bites of infected female Anopheles mosquitoes. It is preventable and curable. In 2019, there were an estimated 229 million cases of malaria worldwide. Malaria is caused by Plasmodium parasites. The parasites are spread to people through the bites of infected female Anopheles mosquitoes, called “malaria vectors.” There are 5 parasite species that cause malaria in humans, and 2 of these species – P. falciparum and P. vivax – pose the greatest threat. Malaria is an acute febrile illness. In a non-immune individual, symptoms usually appear 10–15 days after the infective mosquito bite.
The first symptoms – fever, headache, and chills – may be mild and difficult to recognize as malaria. If not treated within 24 hours, P. falciparum malaria can progress to severe illness, often leading to death. Early diagnosis and treatment of malaria reduces disease and prevents deaths. Antimalarial medicines can also be used to prevent malaria. For travellers, malaria can be prevented through chemoprophylaxis, which suppresses the blood stage of malaria infections, thereby preventing malaria disease. The most common antimalarial drugs include: Chloroquine phosphate, Chloroquine is the preferred treatment for any parasite that is sensitive to the drug.
Latest Breakthroughs and Developments in the Malaria Treatment Landscape
Cipargamin is the first antimalarial drug candidate with a novel mechanism of action to achieve positive clinical proof-of-concept in over 20 years. Cipargamin, the first compound in the spiroindolone class of treatment, works through a novel mechanism of action that involves inhibition of a P-type cation-transporter ATPase4 (PfATP4), which regulates sodium concentration in the parasite. Because Cipargamin also appears to be effective against the sexual forms of the parasite, it could potentially help prevent disease transmission. Cipargamin was tested in adult patients with uncomplicated malaria and showed a median parasite clearance time of 12 hours, including in patients with resistant infections. Currently the product is in Phase II stage of development for the treatment of Malaria.
Malaria Emerging Drugs
Malaria Pipeline Therapeutics Analysis
There are approx. 15+ key companies which are developing the therapies for Malaria. The companies which have their Malaria drug candidates in the most advanced stage, i.e. Phase I include Novartis.
For further information, refer to the detailed report @ Malaria Emerging Therapies
DelveInsight’s Malaria Pipeline Report covers around 20+ products under different phases of clinical development-
Scope of the Malaria Pipeline Report
Table of Content
Got Queries? Reach out for more information on the Malaria Pipeline Report- Malaria Pipeline Therapeutic Assessment
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/